Mersana Therapeutics, Inc. (MRSN)

Mersana Therapeutics Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Assets

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Sep 30, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Cash & Equivalents	56.39	107.75	174.56	128.89	177.95	255.09
Short-Term Investments	-	26.87	34.52	151.83	-	-
Cash & Short-Term Investments	56.39	134.62	209.08	280.71	177.95	255.09
Cash Growth	-63.66%	-35.61%	-25.52%	57.75%	-30.24%	155.63%
Receivables	0.17	-	-	30	-	-
Prepaid Expenses	2.95	2.28	4.97	8.51	10.95	3.49
Total Current Assets	59.99	136.9	214.06	319.22	188.9	258.58
Property, Plant & Equipment	2.2	6.78	11.53	14.46	14.86	12.67
Other Long-Term Assets	0.5	0.98	0.48	0.66	2.36	2.15
Total Assets	62.69	144.66	226.06	334.34	206.11	273.4

Liabilities

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Sep 30, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Accounts Payable	2.39	4.33	7.32	13.95	12.32	8.34
Accrued Expenses	14.81	18.96	20.85	43.18	28.72	16.15
Current Portion of Long-Term Debt	-	12.5	2.08	-	-	-
Current Portion of Leases	2.29	3.9	3.4	3.04	2.54	1.53
Current Unearned Revenue	23.77	22.17	28.15	30.61	3.94	3.99
Other Current Liabilities	-	0.59	1.84	0.75	-	-
Total Current Liabilities	43.27	62.46	63.64	91.53	47.52	30
Long-Term Debt	-	10.95	23.15	24.93	24.63	4.98
Long-Term Leases	-	1.3	5.2	8.78	11.7	10.33
Long-Term Unearned Revenue	78.95	79.46	97.17	117.04	-	-
Other Long-Term Liabilities	-	-	0	-	0.53	-
Total Liabilities	122.22	154.17	189.16	242.28	84.37	45.31

Shareholders' Equity

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Sep 30, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Common Stock	-	0.01	0.01	0.01	0.01	0.01
Additional Paid-In Capital	891.98	886.02	863.24	746.89	572.21	508.5
Retained Earnings	-951.52	-895.55	-826.36	-654.69	-450.48	-280.42
Comprehensive Income & Other	-	0.01	0.01	-0.15	-	-
Total Common Equity	-59.54	-9.51	36.9	92.06	121.74	228.09
Shareholders' Equity	-59.54	-9.51	36.9	92.06	121.74	228.09
Total Liabilities & Equity	62.69	144.66	226.06	334.34	206.11	273.4

Additional Metrics

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Sep 30, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Total Debt	2.29	28.65	33.83	36.75	38.86	16.84
Net Cash (Debt)	54.1	105.97	175.25	243.97	139.08	238.26
Net Cash Growth	-56.25%	-39.53%	-28.17%	75.41%	-41.62%	159.92%
Net Cash Per Share	10.87	21.62	37.73	65.12	49.26	96.87
Filing Date Shares Outstanding	5	4.99	4.85	4.32	3.34	2.76
Total Common Shares Outstanding	5	4.63	4.83	4.21	2.95	2.75
Working Capital	16.72	74.45	150.42	227.69	141.38	228.58
Book Value Per Share	-11.91	-2.06	7.64	21.89	41.29	82.83
Tangible Book Value	-59.54	-9.51	36.9	92.06	121.74	228.09
Tangible Book Value Per Share	-11.91	-2.06	7.64	21.89	41.29	82.83
Machinery	2.45	10.29	10.7	9.78	7.74	7.48
Leasehold Improvements	2.21	2.21	2.21	1.94	1.91	1.89

SEC Filings: 10-K · 10-Q

Data Source: S&P Global Market Intelligence Last updated: Sep 30, 2025

Financial data is provided by S&P Global Market Intelligence and updates within hours after each earnings release, which is every three months for this company.

Update frequency:

Quarterly

Last checked:

Jan 1, 2000

Data Sources Report a data error